Litigation Details for AstraZeneca AB v. Apotex Inc. (D. Del. 2024)
✉ Email this page to a colleague
AstraZeneca AB v. Apotex Inc. (D. Del. 2024)
Docket | ⤷ Sign Up | Date Filed | 2024-05-06 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:1 Patent Infringement | Assigned To | Unassigned Judge |
Jury Demand | None | Referred To | |
Patents | 7,919,598; 8,501,698; 8,685,934 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in AstraZeneca AB v. Apotex Inc.
Details for AstraZeneca AB v. Apotex Inc. (D. Del. 2024)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
0000-00-00 | External link to document | |||
2024-10-24 | 16 | Brief - Opening Brief in Support | for any of U.S. Patent Nos. 7,919,598 (“the ’598 patent”), 8,501,698 (“the ’698 patent”), 8,685,934 (“…(“the ’934 patent”), and 9,616,028 (“the ’028 patent) (collectively, the “Patents-in-Suit”), does not… 35 U.S.C. §§ 102 or 103 for the ’598 and ’698 patents. Thus, even if Apotex’s proposed reliance on its… PageID #: 262 construed claim of the ’598 patent.”) (emphases added)), cannot be maintained as Apotex…expiration of AstraZeneca’s Orange Book-listed Patents-in-Suit. The filing of an ANDA is a statutory | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |